Serious maternal morbidity (renal or respiratory failure, cardiac arrest or multiple organ failure) · Women (aged between 20 and 40) diagnosed with primary PPH following 'normal' vaginal birth and unresponsive to medical treatment (Ashraf…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with total blood loss 1000 mL or more after randomisation · Women (aged between 20 and 40) diagnosed with primary PPH following 'normal' vaginal birth and unresponsive to medical treatment (Ashraf…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean blood loss (mL) (trialist defined) · Women (aged between 20 and 40) diagnosed with primary PPH following 'normal' vaginal birth and unresponsive to medical treatment (Ashraf…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion (red cell or whole blood) · Women (aged between 20 and 40) diagnosed with primary PPH following 'normal' vaginal birth and unresponsive to medical treatment (Ashraf…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects of the intervention (e.g. trauma, necrosis) ‐ fever · Women (aged between 20 and 40) diagnosed with primary PPH following 'normal' vaginal birth and unresponsive to medical treatment (Ashraf…
It is very uncertain whether intrauterine balloon tamponade (condom‐loaded catheter) changes side effects of the intervention (e.g. trauma, necrosis) ‐ fever compared with uterovaginal packing (intrauterine tamponade versus another… (very low certainty).
1 finding from 1 review
Adverse events · Adults with aggressive periodontitis
The review found no eligible studies for this question.
1 finding from 1 review
Percentage of closed pockets · Adults with aggressive periodontitis
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · Adults with aggressive periodontitis
Doxycycline + SRP showed no clear difference in adverse events compared with amoxicillin + metronidazole + SRP; GRADE not reported.
1 finding from 1 review
Percentage of bleeding on probing (BOP) · Adults with aggressive periodontitis
The review found no eligible studies for this question.
1 finding from 1 review
Clinical remission · Patients with acute pouchitis
It is very uncertain whether ciprofloxacin changes clinical remission compared with metronidazole (very low certainty).
1 finding from 1 review
Clinical improvement · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of clinical remission · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No episodes of acute pouchitis · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with acute pouchitis
It is very uncertain whether ciprofloxacin changes adverse events compared with metronidazole (very low certainty).
1 finding from 1 review
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in treatment response at 52 weeks: complete remission (primary outcome… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in treatment response at 52 weeks: partial remission (primary outcome 3) compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
Sustainable remission between 52 and 78 weeks: complete or partial remission (primary outcome 1, 2, 3) · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in sustainable remission between 52 and 78 weeks: complete or partial… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
CKD or death: death by 52 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
CKD or death: 50% decline in GFR by 78 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review